Dating after cancer can be scary, but dating with cancer can be down right daunting.
A few years after my marriage ended, I finally tried to date. I frequently see blogs and articles from young people in the cancer world addressing the concerns and stress of dating after cancer. But what about the conversations that address dating with cancer? After all, the one thing that was keeping me from dating was my disease.
I didn't have the energy to explain that every other weekend I wouldn't be available while recovering from treatment, or that my pixie haircut wasn't by choice, or that you can have cancer without actually looking like a cancer patient. Dating as a healthy person is stressful enough. I wasn't sure I was up for the added burden of explaining all the fun that came along with dating a girl like me — a girl who had cancer, but wasn't necessarily dying from it.
I made my dating profile as vague as possible, knowing a few clicks in a search engine would bring up plenty of evidence about who I was and with what I was living. It would be enough evidence for most men to swipe left and move on to a less complicated girl. I didn't want an online search to muddy the water before they had a chance to meet me, and I wanted to be the one to control the release of information in proper context. I wanted them to see that cancer aside, I lived a fairly normal life.
On the few dates I went on, inevitably the can of cancerous worms would be opened. And as surprised and interested as they were to hear about my diagnosis years earlier, not once did anyone ask about the outcome. They never asked if I still had cancer. I don't know if it's because they didn't want to know the answer, naively made assumptions since I was healthily sitting in front of them, or were just generally not interested in me enough to ask. Considering I wasn't interested in any of them, I took it as confirmation, thanked them for the date, went home and swiped left.
My dip into the world of dating only lasted a few months, and it wasn't the dread of explaining my disease that ultimately led me to delete the dating apps. I was about to start a new treatment that would leave me with a red, rash-covered face and skin. I knew it wasn't the right time to be competing with all my perfectly made-up peers using beauty apps to look their finest. I didn't want the first words out of my month to be an explanation as to why the photos on my dating profile didn't match the dry, red, bumpy face that say down next to my date at the bar.
I didn't consider dating with cancer to be a fail, but merely a few months of distraction from my rather-contented life as a single girl who just happens to have cancer. It was like I got to go out in the world and pretend to be normal again for a few, fleeting moments. And then it happened. As every well-meaning aunt likes to tell any single person within reach, the right person will come along when you least expect it. We met at a funeral a week after I started that rash-inducing targeted therapy. It was when and where I very much least expected it, and to my relief he very much saw past my disease.
Presurgical Opdivo, Chemo See High Response in Early-Stage Breast Cancer
December 9th 2023Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.
Read More
Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer
November 30th 2023Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Listen
Tecentriq Plus Perjeta, Herceptin, Chemo Does Not Improve pCR in HER2+ Breast Cancer
December 8th 2023A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.
Read More
Kadcyla Is the ‘First Therapy to Show Improved Survival’ in a Breast Cancer Subset
December 8th 2023Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.
Read More